Navigation Links
Varian, Inc. Acquires Oxford Diffraction, Ltd.
Date:4/6/2008

from the same dedicated and attentive customer support and applications team at Oxford Diffraction but with the additional resources of Varian's worldwide support organization," said David Warner, Customer Support Group Manager at Oxford Diffraction. "One of our strengths has been a tailored and personal support experience for our customers. This will not change since our customers will be dealing with the same people. The support of the Varian network will simply enhance this experience."

Varian, Inc. acquired Oxford Diffraction for approximately $37 million in cash and assumed net debt (subject to certain net asset adjustments). The transaction also includes an opportunity for additional purchase price payments over three years, dependent on future financial performance. Those future payments could total up to $10 million if aggressive performance targets are achieved. Oxford Diffraction generated revenues of approximately $15 million for the twelve months ended March 31, 2008. Varian, Inc. will provide further details on the acquisition during its webcast conference call to review its fiscal year 2008 second quarter financial results later this month.

This acquisition is part of Varian, Inc.'s strategy to strengthen the company's portfolio of information-rich detection products, through internal research and development as well as the acquisition of complementary products and technologies.

Varian, Inc. is a leading worldwide supplier of scientific instruments and vacuum technologies for life science and industrial applications. The company provides complete solutions, including instruments, vacuum products, laboratory consumable supplies, software, training and support through its global distribution and support systems. Varian, Inc. employs approximately 3,900 people worldwide and operates manufacturing facilities in North America, Europe and Asia Pacific. Varian, Inc. had fiscal year 2007 sales of $921 million, and its common stock is trade
'/>"/>

SOURCE Varian, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast, Ovarian, Uterine or Colorectal Cancer
2. Varian, Inc. Offers New Products for the Rapid Purification of Synthetic Oligonucleotides.
3. Varian, Inc. Acquires Analogix Business
4. Varian, Inc. CEO to Speak at JPMorgan Healthcare Conference
5. Varian, Inc. Board Authorizes New $100 Million Stock Repurchase Program
6. New High Performance Gas Chromatographs and Analysis Solutions From Varian, Inc. Offer Enhanced Performance and Capabilities for More Applications
7. New Ion Trap Mass Spectrometers From Varian, Inc. Offer the Ultimate in Sensitive Detection and High Productivity
8. Cogdell Spencer Inc. Acquires Summit Professional Plaza I and II in Brunswick, Georgia
9. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
10. Food Bank For New York City Acquires FoodChange
11. Concentra Acquires Assets of Renew Health & Wellness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...he University of Texas Health Science Center at Ho...ce in Aging Studies (TEXAS), to promote geriatrics...million award from the Donald W. Reynolds Foundati...ll allow us to teach geriatric medicine principles...to practicing physicians. With the reach of Lyndon...
(Date:11/21/2008)...PRNewswire-FirstCall/ -- The Providence Service,C...Craig A. Norris, the Company,s,Chief Operating Of...f,Directors. Mr. Norris, appointment fills the v...en I. Geringer and returns the board to six member... the Board. , Mr. Norris, age 41, has been ...
(Date:11/21/2008)...ved effective against Lennox-Gastaut syndrome , ...w drug called Banzel (rufinamide) has been approve...f epilepsy called Lennox-Gastaut syndrome, the U.S..., The approval was based on results of a four-mo...o 30. Compared to patients who took a placebo, tho...
(Date:11/21/2008)...21 New research at Wes...eless, spitless tobacco product aimed at young adu... that RJ Reynolds, Camel Snus - touted as a social...surprisingly high levels of nicotine. , , "...snuff products," said Bruce Adkins of the state Di...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3
...earchers from the Johns Hopkins Department of had ...y in the heart after a heart attack. // The resea...called SPECT/CT, to successfully trace stem cells’... injected into the body to treat animal hearts dam...
...ple suffering from anorexia nervosa have the simil...d other emotional disorders. // The study was publ...l Psychiatry. Previous evidence has suggested that...nin (a brain chemical involved in communication be...
...ral tube defects are congenital deformities that a...ifida and anencephaly are the two most common form...s paralysis in spina bifida and fatal brain deform...t can be diagnosed by antenatal ultrasound, nothin...
... aortic valve in the heart is the valve that gover...ely the aorta, which supplies blood to various org...wing back inside the heart from the rest of the bo...heart depends on the proper functioning of the aor...
Other Medicine News:Health News:Percutaneous aortic valve replacement- a revolution in Cardiac Surgery 2
(Date:11/20/2008)...LE, Calif., Nov. 20 Bion... will present results from the Phase 1B,clinical ...tastatic breast,cancer, BZL101, at the Society fo...erence in Atlanta, Georgia. The Company,s oral pr... and will be presented as a part of the Best of th...
(Date:11/20/2008)...SO, Norway, November 20 The Scandi...arma has announced results of studies on its,lead...AC in Washington, DC,the studies showed that the...cteriocidal effect, significantly better towards k...ogenes than marketed gold standard drugs. In,addi...
(Date:11/19/2008)...ELLE, N.Y., Nov. 19 Biotech scient...es to toxicology research to better understand the...organ systems, reports Genetic Engineering & ...nterested in figuring out a new compound,s mechani...e toxicology technique, according to the November ...
(Date:11/18/2008)... Pa., Nov. 18 Arlington Medical Re...ligence for the pharmaceutical and diagnostic,ima...L Behring,s Privigen was,sold in the U.S. during ...,brand of intravenous immune globulin (IVIG) and w... a product created from the blood plasma of thousa...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Cardiome Reports First Quarter Results 19236 1Cardiome Reports First Quarter Results 19236 2Cardiome Reports First Quarter Results 19236 3Cardiome Reports First Quarter Results 19236 4Cardiome Reports First Quarter Results 19236 5Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 1Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 2Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 3Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 4Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 5Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 6Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 7Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 8Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 9Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 10Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 11Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 12Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 1Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 2Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 3Quality Lags at Safety Net Hospitals 19232 1Quality Lags at Safety Net Hospitals 19232 2Quality Lags at Safety Net Hospitals 19232 3
..., 2007 /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. ...elanoma vaccine clinical trial and data from the P... vaccine clinical trial will be,presented at the 2...3rd annual meeting in Chicago on June 1-5 2007. , ...cal and immunological responses in patients with m...
...e Patients Receiving Combination of,Bavituximab Pl...sponse or Stable Disease - , - 75% of Patients ...ine , ,Achieved Objective Tumor Response...Receiving Combination of Bavituximab Plus , ... Response - , - Trial Results Support Advanc...
Other Medicine Technology:IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 2IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 3IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 4IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 5IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 6Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 2Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 3Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 4Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 5
More than 200 key diagnostic and treatment tables culled from Tierney's Current Medical Diagnostics and Treatment 2003.
Athouritative, on the spot answers for acute care and consultations.
...de includes a specially designed, integrated retra... and handling. The Xstar Blade technology is base...al blades. This proprietary process yields outsta...single-bevel geometry allows the surgeon to create...
...de includes a specially designed, integrated retra... and handling. The Xstar Blade technology is base...al blades. This proprietary process yields outsta...single-bevel geometry allows the surgeon to create...
Medicine Products: